---
title: "Ibrance (palbociclib), all indications: Specific populations questions"
description: "Specific populations questions on Ibrance (palbociclib) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pediatric use and Pregnancy and breastfeeding. Questions: Does Ibrance need a dose adjustment for liver impairment? Does Ibrance need a dose adjustment for kidney impairment? Is Ibrance approved for children? Can Ibrance be used during pregnancy? 3 further questions follow. 7 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/ibrance/specific-populations"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ibrance (palbociclib), all indications: Specific populations questions

Manufacturer: Pfizer Laboratories Div Pfizer Inc  
Prescribing information: [Ibrance](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921), [Ibrance](https://labeling.pfizer.com/ShowLabeling.aspx?id=2191)  
Indication pages: [HR-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer)

## Specific populations

<a id="ibrance-liver-impairment"></a>

### Does Ibrance need a dose adjustment for liver impairment?

> “No dose adjustment is required for patients with mild or moderate hepatic impairment (Child-Pugh classes A and B). For patients with severe hepatic impairment (Child-Pugh class C), the recommended dose of IBRANCE is 75 mg once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=No%20dose%20adjustment%20is%20required%20for,%288.6%29%20and%20Clinical%20Pharmacology%20%2812.3%29%5D.)

> “Review the Full Prescribing Information for the aromatase inhibitor or fulvestrant for dose modifications related to hepatic impairment.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Review%20the%20Full%20Prescribing%20Information,modifications%20related%20to%20hepatic%20impairment.)

<a id="ibrance-kidney-impairment"></a>

### Does Ibrance need a dose adjustment for kidney impairment?

> “No dose adjustment is required in patients with mild, moderate, or severe renal impairment (CrCl >15 mL/min).”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=No%20dose%20adjustment%20is%20required%20in%20patients%20with%20mild%2C,renal%20impairment%20%28CrCl%20%3E15%20mL%2Fmin%29.)

> “The pharmacokinetics of palbociclib have not been studied in patients requiring hemodialysis [see Clinical Pharmacology (12.3)].”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=The%20pharmacokinetics%20of%20palbociclib%20have,hemodialysis%20%5Bsee%20Clinical%20Pharmacology%20%2812.3%29%5D.)

<a id="ibrance-male-fertility"></a>

### Does Ibrance affect male fertility?

> “Based on animal studies, IBRANCE may impair fertility in males of reproductive potential [see Nonclinical Toxicology (13.1)].”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Based%20on%20animal%20studies%2C%20IBRANCE%20may,potential%20%5Bsee%20Nonclinical%20Toxicology%20%2813.1%29%5D.)

> “IBRANCE may impair fertility in males and has the potential to cause genotoxicity. Advise male patients to consider sperm preservation before taking IBRANCE.”

Source: [IBRANCE: PALOMA-2 Efficacy & Safety, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-2/efficacy-safety#:~:text=IBRANCE%20may%20impair%20fertility%20in,sperm%20preservation%20before%20taking%20IBRANCE.)

## Pediatric use

<a id="ibrance-children"></a>

### Is Ibrance approved for children?

> “The safety and effectiveness of IBRANCE in pediatric patients have not been established.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=The%20safety%20and%20effectiveness%20of,patients%20have%20not%20been%20established.)

> “It is not known if IBRANCE is safe and effective in children.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=It%20is%20not%20known%20if%20IBRANCE%20is%20safe%20and%20effective%20in%20children.)

## Pregnancy and breastfeeding

<a id="ibrance-pregnancy"></a>

### Can Ibrance be used during pregnancy?

> “Based on findings from animal studies and its mechanism of action, IBRANCE can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available data in pregnant women to inform the drug-associated risk. In animal reproduction studies, administration of palbociclib to pregnant rats and rabbits during organogenesis resulted in embryo-fetal toxicity at maternal exposures that were ≥4 times the human clinical exposure based on AUC (see Data). Advise pregnant women of the potential risk to a fetus.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Risk%20Summary-,Based%20on%20findings%20from%20animal%20studies%20and%20its%20mechanism%20of,potential%20risk%20to%20a%20fetus.)

<a id="ibrance-contraception"></a>

### How long is birth control needed after stopping Ibrance?

> “Advise females of reproductive potential to use effective contraception during treatment with IBRANCE and for at least 3 weeks after the last dose.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Specific%20Populations%20%288.1%29%5D.-,Advise%20females%20of%20reproductive%20potential%20to%20use%20effective%20contraception%20during,weeks%20after%20the%20last%20dose.)

> “Because of the potential for genotoxicity, advise male patients with female partners of reproductive potential to use effective contraception during treatment with IBRANCE and for 3 months after the last dose [see Nonclinical Toxicology (13.1)].”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Because%20of%20the%20potential%20for%20genotoxicity%2C,dose%20%5Bsee%20Nonclinical%20Toxicology%20%2813.1%29%5D.)

<a id="ibrance-breastfeeding"></a>

### Can Ibrance be used while breastfeeding?

> “There is no information regarding the presence of palbociclib in human milk, its effects on milk production, or the breastfed infant. Because of the potential for serious adverse reactions in breastfed infants from IBRANCE, advise a lactating woman not to breastfeed during treatment with IBRANCE and for 3 weeks after the last dose.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=There%20is%20no%20information%20regarding,weeks%20after%20the%20last%20dose.)

## Related pages
- [Medical information: Ibrance (palbociclib): All indications](https://www.evicenter.com/medical-information/ibrance)
- [Indication](https://www.evicenter.com/medical-information/ibrance/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/ibrance/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/ibrance/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/ibrance/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/ibrance/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/ibrance/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/ibrance/access-and-coverage)
